59 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting.
Cash and Cash Equivalents
The Company … , an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
assets, valuation of deferred income taxes, unrealized tax positions and business combination accounting.
Cash and Cash Equivalents
The Company … , an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
to this Agreement will give rise to any adverse tax consequences to any person pursuant to Section 409A and this Agreement shall be interpreted, applied
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
, unrealized tax positions and business combination accounting.
Cash and Cash Equivalents
The Company considers all highly liquid investments … income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
of a 43.5% tax credit for clinical expenses incurred in Australia. The location of the proof-of-concept (“POC”) plan has not been determined at this time … , and we will determine the ultimate location based on availability of facilities and patient population, costs, tax credits and centers of excellence
424B3
tftqdcjs6kd5m
16 Apr 24
Prospectus supplement
5:45pm
10-K
EX-3.3
9tywx5
16 Apr 24
Annual report
4:48pm
10-K
EX-97.1
ult98kssmv2skhpq0
16 Apr 24
Annual report
4:48pm
10-K
EX-19.1
hahyhhonq52
16 Apr 24
Annual report
4:48pm
10-K
op2fc3c4rzues
16 Apr 24
Annual report
4:48pm
S-8
EX-4.5
ehc984j9d 9oo1ufrs3h
12 Apr 24
Registration of securities for employees
7:22pm
S-8
EX-4.6
awbaun0ym0g igx
12 Apr 24
Registration of securities for employees
7:22pm
8-K
EX-99.1
bkj3xhh26xea
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-1.1
bp8seo4uk41tzw0
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
8-K
EX-4.1
y3m0hlj
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
cy5umb38hhi31k
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
ch2ox1bur0ra22bih
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
xkwds 869z
12 Feb 24
Free writing prospectus
8:09am